人类免疫缺陷病毒相关隐球菌脑膜炎的诊治现状和挑战

摘要/Abstract

中图分类号:

R715.2

赵含丹, 许利军. 人类免疫缺陷病毒相关隐球菌脑膜炎的诊治现状和挑战[J]. 诊断学理论与实践, 2022, 21(04): 419-424.

参考文献50

[1]	Williamson PR, Jarvis JN, Panackal AA, et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy[J]. Nat Rev Neurol, 2017, 13(1):13-24. doi:10.1038/nrneurol.2016.167pmid:27886201
[2]	中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中国艾滋病性病, 2021, 27(11):1182-1201.
	AIDS and hepatitis C group, infectious diseases branch, Chinese Medical Association, China Center for Disease Control and prevention. China AIDS diagnosis and treatment guide(2021 Edition)[J]. Chin J AIDS & STD, 2021, 27(11):1182-1201.
[3]	Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options[J]. Clin Epidemiol, 2014, 6:169-182. doi:10.2147/CLEP.S38850pmid:24872723
[4]	Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS[J]. AIDS, 2009, 23(4):525-530. doi:10.1097/QAD.0b013e328322ffacpmid:19182676
[5]	Jarvis JN, Tenforde MW, Lechiile K, et al. Evaluation of a novel semiquantitative cryptococcal antigen lateral flow assay in patients with advanced HIV disease[J]. J Clin Microbiol, 2020, 58(9):e00441-20.
[6]	Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis[J]. Lancet Infect Dis, 2017, 17(8):873-881. doi:S1473-3099(17)30243-8pmid:28483415
[7]	Toborek M, Lee YW, Flora G, et al. Mechanisms of the blood-brain barrier disruption in HIV-1 infection[J]. Cell Mol Neurobiol, 2005, 25(1):181-199. pmid:15962513
[8]	Kanmogne GD, Schall K, Leibhart J, et al. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis[J]. J Cereb Blood Flow Metab, 2007, 27(1):123-134. doi:10.1038/sj.jcbfm.9600330 URL
[9]	Maziarz EK, Perfect JR. Cryptococcosis[J]. Infect Dis Clin North Am, 2016, 30(1):179-206. doi:10.1016/j.idc.2015.10.006 URL
[10]	Zhao H, Zhou M, Zheng Q, et al. Clinical features and outcomes of cryptococcemia patients with and without HIV infection[J]. Mycoses, 2021, 64(6):656-667. doi:10.1111/myc.13261pmid:33609302
[11]	Wake RM, Britz E, Sriruttan C, et al. High cryptococcal antigen titers in blood are predictive of subclinical cryptococcal meningitis among human immunodeficiency virus-infected patients[J]. Clin Infect Dis, 2018, 66(5):686-692. doi:10.1093/cid/cix872pmid:29028998
[12]	Robertson EJ, Najjuka G, Rolfes MA, et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis[J]. J Infect Dis, 2014, 209(1):74-82. doi:10.1093/infdis/jit435pmid:23945372
[13]	Antinori S. New Insights into HIV/AIDS-Associated Cryptococcosis[J]. ISRN AIDS, 2013, 2013:471363.
[14]	Xu L, Xu Y, Zheng Y, et al. Differences in cytokine and chemokine profiles in cerebrospinal fluid caused by the etiology of cryptococcal meningitis and tuberculous meningitis in HIV patients[J]. Clin Exp Immunol, 2021, 206(1):82-90. doi:10.1111/cei.13644pmid:34287847
[15]	Xu L, Guo Y, Zhao Y, et al. Chemokine and Cytokine cascade caused by skewing of the Th1-Th2 balance is associated with high intracranial pressure in HIV-associa-ted cryptococcal meningitis[J]. Mediators Inflamm, 2019, 2019:2053958.
[16]	Jiang YK, Wang RY, Zhou LH, et al. Cerebrospinal fluid cytokine and chemokine patterns correlate with prognosis of HIV-uninfected cryptococcal meningitis: A prospective observational study[J]. Front Immunol, 2022, 13:993495.
[17]	刘正印, 王贵强, 朱利平, 等. 隐球菌性脑膜炎诊治专家共识[J]. 中华内科杂志, 2018, 57(5):317-323. pmid:29747285
	Liu ZY, Wang GQ, Zhu LP, et al. Expert consensus on the diagnosis and treatment of cryptococcal meningitis[J]. Chin J Intern Med, 2018, 57(5):317-323. doi:10.3760/cma.j.issn.0578-1426.2018.05.003pmid:29747285
[18]	Xu L, Yu J, Zheng B, et al. HIV infection does not increase 10-week mortality of Chinese cryptococcal meningitis patients[J]. AIDS Res Hum Retroviruses, 2020, 36(9):734-741. doi:10.1089/aid.2020.0001 URL
[19]	Rajasingham R, Wake RM, Beyene T, et al. Cryptococcal Meningitis diagnostics and screening in the era of point-of-care laboratory testing[J]. J Clin Microbiol, 2019, 57(1):e01238-18.
[20]	Boulware DR, Rolfes MA, Rajasingham R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast[J]. Emerg Infect Dis, 2014, 20(1):45-53. doi:10.3201/eid2001.130906pmid:24378231
[21]	潘孝彰, 卢洪洲, 沈银忠. 冀望病原微生物的诊断有更大发展[J]. 诊断学理论与实践, 2010, 9(6):541-544.
	Pan XZ, Lu HZ, Shen YZ. Prospects on advances in diagnosis of pathogenic microorganisms[J]. J Diagn Concepts & Pract, 2010, 9(6):541-544.
[22]	“十三五”国家科技重大专项艾滋病机会性感染课题组. 艾滋病合并隐球菌病临床诊疗的专家共识[J]. 西南大学学报(自然科学版), 2020, 42(7):1-19.
	AIDS-Associated Opportunistic Infections Research Group of the National Science and Technology Marjor Project of China During the 13th Fiver-Year Plan Period. Expert consensus on the diagnosis and treatment of cryptococcosis in AIDS patients[J]. J Southwest Univ(Nat Sci), 2020, 42(7):1-19.
[23]	Tang MW, Clemons KV, Katzenstein DA, et al. The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time[J]. Crit Rev Microbiol, 2016, 42(4):634-642. doi:10.3109/1040841X.2014.982509pmid:25612826
[24]	Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: What do we know now[J]. Fungal Genet Biol, 2015, 78:49-54. doi:10.1016/j.fgb.2014.10.003pmid:25312862
[25]	Gushiken AC, Saharia KK, Baddley JW. Cryptococcosis[J]. Infect Dis Clin North Am, 2021, 35(2):493-514. doi:10.1016/j.idc.2021.03.012 URL
[26]	Wilson MR, Sample HA, Zorn KC, et al. Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis[J]. N Engl J Med, 2019, 380(24):2327-2340. doi:10.1056/NEJMoa1803396 URL
[27]	Chiu CY, Miller SA. Clinical metagenomics[J]. Nat Rev Genet, 2019, 20(6):341-355. doi:10.1038/s41576-019-0113-7pmid:30918369
[28]	Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection[J]. Annu Rev Pathol, 2019, 14:319-338. doi:10.1146/annurev-pathmechdis-012418-012751pmid:30355154
[29]	WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for The Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection[M]. Geneva: World Health Organization, 2018.
[30]	Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010, 50(3):291-322. doi:10.1086/649858pmid:20047480
[31]	Jarvis JN, Lawrence DS, Meya DB, et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis[J]. N Engl J Med, 2022, 386(12):1109-1120. doi:10.1056/NEJMoa2111904 URL
[32]	Temfack E, Boyer-Chammard T, Lawrence D, et al. New insights into cryptococcus spp. biology and cryptococcal meningitis[J]. Curr Neurol Neurosci Rep, 2019, 19(10):81. doi:10.1007/s11910-019-0993-0 URL
[33]	WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV[M]. Geneva: World Health Organization, 2022.
[34]	Xu L, Tao R, Wu J, et al. Short-course rather than low-dose amphotericin B may exert potential influence on mortality in cryptococcal meningitis patients treated with amphotericin B plus flucytosine alone or in combination with fluconazole[J]. Front Microbiol, 2019, 10:2082. doi:10.3389/fmicb.2019.02082pmid:31551999
[35]	Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes[J]. Clin Infect Dis, 2014, 58(5):736-745. doi:10.1093/cid/cit794pmid:24319084
[36]	Zhou Y, Yang Z, Liu M, et al. Independent risk factors for deaths due to AIDS in Chongqing, China: Does age matter?[J]. Front Med (Lausanne), 2021, 7:586390.
[37]	Wu L, Xiao J, Song Y, et al. The clinical characteristics and outcome of cryptococcal meningitis with AIDS in a tertiary hospital in China: an observational cohort study[J]. BMC Infect Dis, 2020, 20(1):912. doi:10.1186/s12879-020-05661-9pmid:33261581
[38]	Chen J, Zhang R, Shen Y, et al. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis[J]. HIV Med, 2019, 20(1):69-73. doi:10.1111/hiv.12679pmid:30311440
[39]	Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi[J]. Clin Infect Dis, 2010, 50(3):338-344. doi:10.1086/649861pmid:20038244
[40]	Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis[J]. AIDS, 2007, 21(16):2119-2129. doi:10.1097/QAD.0b013e3282a4a64dpmid:18090038
[41]	Yao Y, Zhang JT, Yan B, et al. Voriconazole: a novel treatment option for cryptococcal meningitis[J]. Infect Dis(Lond), 2015, 47(10):694-700.
[42]	Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole[J]. Clin Pharmacokinet, 2006, 45(7):649-663. pmid:16802848
[43]	陶然, 师金川, 郭永征, 等. 两性霉素B去氧胆酸盐、两性霉素B脂质体和伏立康唑诱导治疗HIV相关性隐球菌脑膜炎的效果比较[J]. 新发传染病电子杂志, 2019, 4(2):97-102.
	Tao R, Shi JC, Guo YZ, et al. Comparison of amphotericin B deoxycholate, amphotericin B liposome and voriconazole as induction treatment on HIV-related cryptococcal meningitis[J]. Electron J Emerg Infect Dis, 2019, 4(2):97-102.
[44]	Murphy RA, Hatlen TJ, Moosa MS. High-dose fluconazole consolidation therapy for cryptococcal meningitis in sub-saharan Africa: much to gain, little to lose[J]. AIDS Res Hum Retroviruses, 2018, 34(5):399-403. doi:10.1089/aid.2017.0240 URL
[45]	Rolfes MA, Rhein J, Schutz C, et al. Cerebrospinal fluid culture positivity and clinical outcomes after amphotericin-based induction therapy for cryptococcal meningitis[J]. Open Forum Infect Dis, 2015, 2(4):ofv157. doi:10.1093/ofid/ofv157 URL
[46]	Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial[J]. Lancet Infect Dis, 2014, 14(4):281-290. doi:10.1016/S1473-3099(13)70692-3pmid:24602844
[47]	Tao R, Xu L, Guo Y, et al. Ventriculoperitoneal shunt is associated with increased cerebrospinal fluid protein level in HIV-infected cryptococcal meningitis patients[J]. BMC Infect Dis, 2022, 22(1):286. doi:10.1186/s12879-022-07286-6pmid:35351023
[48]	Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related cryptococcus neoformans disease in the era of highly active antiretroviral therapy[J]. Clin Infect Dis, 2005, 40(7):1049-1052. pmid:15825000
[49]	Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis[J]. N Engl J Med, 2014, 370(26):2487-2498. doi:10.1056/NEJMoa1312884 URL
[50]	Tao R, Peng X, Liu X, et al. Outcome of lenalidomide treatment for cognitive impairment caused by immune reconstitution inflammatory syndrome in patients with HIV-related cryptococcal meningitis[J]. J Inflamm Res, 2022, 15:5327-5336. doi:10.2147/JIR.S374333 URL

人类免疫缺陷病毒相关隐球菌脑膜炎的诊治现状和挑战

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献50

相关文章15

编辑推荐

Metrics

本文评价

[1]	陈志敏, 何浩岚.艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430.
[2]	陈志敏, 刘波, 何浩岚, 何耀祖, 冯理智, 刘新华, 张坚生, 蔡卫平, 李凌华.133例艾滋病合并马尔尼菲篮状菌病死亡病例分析[J]. 诊断学理论与实践, 2022, 21(04): 444-449.
[3]	胡静静, 吕海伟, 荀静娜, 沈银忠, 刘莉, 卢洪洲.2012年至2021年上海市艾滋病合并分枝杆菌感染患者的菌种分布特征[J]. 诊断学理论与实践, 2022, 21(04): 450-455.
[4]	陈宏, 沈银忠.人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[5]	张林, 周莹, 李海聪, 孙美艳, 孙文秀, 陆玲庆, 朱召芹, 唐琪, 张仁芳, 沈银忠, 卢洪洲.HIV病毒过滤器过滤效率的评估实验研究[J]. 诊断学理论与实践, 2019, 18(06): 676-679.
[6]	陶静, 郁晓磊, 张晶, 洪亮, 吴健, 王绪琴, 盖晶, 周艳秋, 郑敏, 薛以乐, 康来仪,.上海市经异性性传播HIV-1感染者的分子流行病学调查[J]. 诊断学理论与实践, 2016, 15(02): 180-184.
[7]	郑敏, 郁晓磊, 倪莹青, 薛以乐, 康来仪,.2013年上海市新发现HIV-1感染者中注射吸毒人群的基因亚型分析[J]. 诊断学理论与实践, 2015, 14(06): 560-564.
[8]	肖宏, 王冯滨, 欧强, 陈楠,.结核性脑膜炎与新型隐球菌脑膜炎的鉴别诊断[J]. 诊断学理论与实践, 2011, 10(06): 560-562.
[9]	郑加麟, 黄云龙, 许东升, 陈生弟,.人类免疫缺陷病毒相关神经认知紊乱[J]. 诊断学理论与实践, 2010, 9(04): 392-395.
[10]	黄琴, 李丹, 孙洪清,.艾滋病合并新生隐球菌脑膜炎的临床分析[J]. 诊断学理论与实践, 2010, 9(03): 252-254.
[11]	李莉, 卢洪洲,.艾滋病患者免疫重建综合征的研究进展[J]. 诊断学理论与实践, 2009, 8(04): 442-444.
[12]	郑晓虹, 张玮, 陈安琪, 薛以乐, 盖晶, 宁镇,.HIV抗原抗体联合检测试剂在高危人群筛查中的应用[J]. 诊断学理论与实践, 2008, 7(02): 168-171.
[13]	龚启明, 孔晓飞, 仇德琪, 陆志檬, 张欣欣,.77例HIV感染者的流行病学特征分析[J]. 诊断学理论与实践, 2007, 6(03): 210-212.
[14]	康来仪,.HIV/AIDS目前实验诊断方法及其价值[J]. 诊断学理论与实践, 2007, 6(03): 185-188.
[15]	薛以乐, 宫菊丽, 郑晓虹, 盖晶, 张玮, 宁镇, 庄鸣华, 潘启超, 卢伟, 钟平, 康来仪,.上海市常住人口HIV-1感染者基因亚型和耐药性突变横断面研究[J]. 诊断学理论与实践, 2007, 6(03): 203-209.